ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca.

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...